BSD Medical has received the US Food and Drug Administration (FDA) 510(k) clearance to market its MicroThermX Microwave Ablation System (MTX-180) for ablation of soft tissue.
The MTX-180 was designed to provide a higher power, optimized system targeted to the growing therapeutic interventional and surgical oncology market.
The MTX-180 utilises synchronous phased array technology that was developed and patented by BSD to deliver targeted microwave energy to ablate (destroy) soft tissue.
The MTX-180 includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system, that allows delivery of higher power levels using a single generator which is controlled utilising an interactive, touch screen monitor that allows the operator to quickly and easily control the treatment.
BSD president Harold Wolcott said that the MTX-180 represents a significant advance in the firm’s strategy to diversify products and increase revenue.
“The soft tissue ablation world market potential is estimated to exceed $2bn. We believe that the MicroThermX System provides significant advantages over currently available devices that will allow us to capitalize on this rapidly expanding market,” Wolcott said.